David J Friedman

List of Publications by Year
in descending order

73 papers	8,426 citations	117625 34 h-index	102487 66 g-index
74 all docs	74 docs citations	74 times ranked	10172 citing authors

#	Article	IF	Citations
1	Background polygenic risk modulates the association between glaucoma and cardiopulmonary diseases and measures: an analysis from the UK Biobank. British Journal of Ophthalmology, 2023, 107, 1112-1118.	3.9	4
2	DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants. Journal of the American Society of Nephrology: JASN, 2022, 33, 889-907.	6.1	15
3	Treatment potential in APOL1-associated nephropathy. Current Opinion in Nephrology and Hypertension, 2022, 31, 442-448.	2.0	7
4	Biomarkers of kidney injury among children in a high-risk region for chronic kidney disease of uncertain etiology. Pediatric Nephrology, 2021, 36, 387-396.	1.7	24
5	APOL1 Nephropathy: From Genetics to Clinical Applications. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 294-303.	4.5	119
6	COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation. Journal of the American Society of Nephrology: JASN, 2021, 32, 1-2.	6.1	16
7	Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	31
8	A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis. Kidney International, 2021, , .	5.2	8
9	APOL1 and Kidney Disease: From Genetics to Biology. Annual Review of Physiology, 2020, 82, 323-342.	13.1	81
10	Urinary Metals Concentrations and Biomarkers of Autoimmunity among Navajo and Nicaraguan Men. International Journal of Environmental Research and Public Health, 2020, 17, 5263.	2.6	14
11	Circulating testican-2 is a podocyte-derived marker of kidney health. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25026-25035.	7.1	19
12	Racial and Ethnic Disparities in Seasonal Influenza Vaccination among Dialysis Facilities in the United States. Journal of the American Society of Nephrology: JASN, 2020, 31, 2117-2121.	6.1	12
13	The Genetic Architecture of Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 268-275.	4.5	19
14	Gait and Balance as Predictors or Mediators of Falls in Glaucoma. Innovation in Aging, 2020, 4, 770-771.	0.1	0
15	Comparing Longitudinal Changes in Physical Activity and Fear of Falling in Non-Fallers, Fallers, and Injurious Fallers. Innovation in Aging, 2020, 4, 770-770.	0.1	0
16	Contributions of Rare Gene Variants to Familial and Sporadic FSGS. Journal of the American Society of Nephrology: JASN, 2019, 30, 1625-1640.	6.1	42
17	Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background. Kidney International, 2019, 96, 1303-1307.	5.2	43
18	APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore. Journal of the American Society of Nephrology: JASN, 2019, 30, 2355-2368.	6.1	64

#	Article	IF	Citations
19	APOL1 gene variants and kidney disease in whites: the cardiovascular health study. Nephrology Dialysis Transplantation, 2019, 34, 2155-2156.	0.7	0
20	Genetic and Developmental Factors in Chronic Kidney Disease Hotspots. Seminars in Nephrology, 2019, 39, 244-255.	1.6	18
21	APOL1-Associated Kidney Disease in Brazil. Kidney International Reports, 2019, 4, 923-929.	0.8	24
22	Prevalence and Risk Factors for CKD Among Brickmaking Workers in La Paz Centro, Nicaragua. American Journal of Kidney Diseases, 2019, 74, 239-247.	1.9	35
23	Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3712-3721.	7.1	64
24	Epidemiology, molecular, and genetic methodologies to evaluate causes ofÂCKDuÂaroundÂthe world: report of the Working GroupÂfrom the ISN InternationalÂConsortium ofÂCollaborators onÂCKDu. Kidney International, 2019, 96, 1254-1260.	5.2	16
25	Comment on Sarathkumara et al.: Exposure to Hantavirus is a Risk Factor Associated with Kidney Diseases in Sri Lanka: A Cross Sectional Study. Viruses, 2019, 11, 1147.	3.3	0
26	Genes and environment in chronic kidney disease hotspots. Current Opinion in Nephrology and Hypertension, 2019, 28, 87-96.	2.0	13
27	The Glomerular Disease Study and Trial Consortium: A Grassroots Initiative to Foster Collaboration and Innovation. Kidney International Reports, 2019, 4, 20-29.	0.8	11
28	Investigating Possible Infectious Causes of Chronic Kidney Disease of Unknown Etiology in a Nicaraguan Mining Community. American Journal of Tropical Medicine and Hygiene, 2019, 101, 676-683.	1.4	21
29	UBD modifies APOL1 -induced kidney disease risk. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3446-3451.	7.1	52
30	A null variant in the apolipoprotein L3 gene is associated with non-diabetic nephropathy. Nephrology Dialysis Transplantation, 2018, 33, 323-330.	0.7	25
31	Modulation of tubular solute reuptake in UMOD knockout mice. American Journal of Physiology - Renal Physiology, 2018, 315, F238-F240.	2.7	1
32	Exome Sequencing for CKD Diagnosis: Coming Soon to a Clinic Near You?. American Journal of Kidney Diseases, 2018, 72, 761-763.	1.9	0
33	Acute Kidney Injury in Sugarcane Workers at Risk for Mesoamerican Nephropathy. American Journal of Kidney Diseases, 2018, 72, 475-482.	1.9	62
34	Most ApoL1 Is Secreted by the Liver. Journal of the American Society of Nephrology: JASN, 2017, 28, 1079-1083.	6.1	44
35	A Brief History of APOL1 : A Gene Evolving. Seminars in Nephrology, 2017, 37, 508-513.	1.6	19
36	Apolipoprotein L1 and Kidney Disease in African Americans. Trends in Endocrinology and Metabolism, 2016, 27, 204-215.	7.1	72

#	Article	IF	Citations
37	Characterization of Mesoamerican Nephropathy in a Kidney Failure Hotspot in Nicaragua. American Journal of Kidney Diseases, 2016, 68, 716-725.	1.9	47
38	Structural characterization of the Câ€terminal coiledâ€coil domains of wildâ€type and kidney diseaseâ€associated mutants of apolipoprotein L1. FEBS Journal, 2016, 283, 1846-1862.	4.7	27
39	APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 398-403.	2.4	78
40	APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 830-837.	7.1	170
41	Urine biomarkers of kidney injury among adolescents in Nicaragua, a region affected by an epidemic of chronic kidney disease of unknown aetiology. Nephrology Dialysis Transplantation, 2016, 31, 424-432.	0.7	56
42	Variation in Glucose Homeostasis Traits Associated With P2RX7 Polymorphisms in Mice and Humans. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E688-E696.	3.6	26
43	Re-Sequencing of the <i>APOL1</i>-<i>APOL4</i> and <i>MYH9</i> Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression. American Journal of Nephrology, 2015, 42, 99-106.	3.1	13
44	Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney International, 2015, 87, 332-342.	5.2	278
45	Copy Number Variation at the APOL1 Locus. PLoS ONE, 2015, 10, e0125410.	2.5	17
46	Increased Burden of Cardiovascular Disease in Carriers of APOL1 Genetic Variants. Circulation Research, 2014, 114, 845-850.	4.5	141
47	Single Nucleotide Polymorphisms at the TNFAIP3/A20 Locus and Susceptibility/Resistance to Inflammatory and Autoimmune Diseases. Advances in Experimental Medicine and Biology, 2014, 809, 163-183.	1.6	26
48	Evolution of the primate trypanolytic factor APOL1. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2130-9.	7.1	183
49	Molecular one-upmanship. Nature, 2013, 501, 322-323.	27.8	6
50	Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure. Science Translational Medicine, 2013, 5, 175ra29.	12.4	149
51	APOL1 variants and kidney disease in people of recent African ancestry. Nature Reviews Nephrology, 2013, 9, 240-244.	9.6	77
52	Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies. PLoS Genetics, 2012, 8, e1003032.	3.5	78
53	APOL1 and kidney disease. Current Opinion in Nephrology and Hypertension, 2012, 21, 179-182.	2.0	49
54	Impact of activated vitamin D on insulin resistance in nondiabetic chronic kidney disease patients. Clinical Endocrinology, 2012, 77, 56-61.	2.4	8

#	Article	IF	Citations
55	Genetic Variation in APOL1 Associates with Younger Age at Hemodialysis Initiation. Journal of the American Society of Nephrology: JASN, 2011, 22, 2091-2097.	6.1	99
56	APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 2129-2137.	6.1	713
57	Population-Based Risk Assessment of APOL1 on Renal Disease. Journal of the American Society of Nephrology: JASN, 2011, 22, 2098-2105.	6.1	203
58	Genetics of kidney failure and the evolving story of APOL1. Journal of Clinical Investigation, 2011, 121, 3367-3374.	8.2	108
59	Thereâ€™s a goat behind door number 3: from Monty Hall to medicine. Journal of Clinical Investigation, 2011, 121, 3819-3821.	8.2	3
60	The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans. Journal of the American Society of Nephrology: JASN, 2010, 21, 1422-1426.	6.1	242
61	Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. Science, 2010, 329, 841-845.	12.6	1,725
62	CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16788-16793.	7.1	255
63	FunctionalENTPD1Polymorphisms in African Americans With Diabetes and End-Stage Renal Disease. Diabetes, 2009, 58, 999-1006.	0.6	32
64	Klotho Variants and Chronic Hemodialysis Mortality. Journal of Bone and Mineral Research, 2009, 24, 1847-1855.	2.8	54
65	Deletion of Cd39/Entpd1 Results in Hepatic Insulin Resistance. Diabetes, 2008, 57, 2311-2320.	0.6	89
66	Tubuloglomerular feedback and renin secretion in NTPDase1/CD39-deficient mice. American Journal of Physiology - Renal Physiology, 2008, 294, F965-F970.	2.7	24
67	The Vascular Ectonucleotidase ENTPD1 Is a Novel Renoprotective Factor in Diabetic Nephropathy. Diabetes, 2007, 56, 2371-2379.	0.6	37
68	Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. Journal of Experimental Medicine, 2007, 204, 1257-1265.	8.5	2,000
69	CD39 and control of cellular immune responses. Purinergic Signalling, 2007, 3, 171-180.	2.2	233
70	Functional Comparison of Mouse slc26a6 Anion Exchanger with Human SLC26A6 Polypeptide Variants. Journal of Biological Chemistry, 2005, 280, 8564-8580.	3.4	137
71	Structure-function relationships of AE2 regulation by Ca i 2 + -sensitive stimulators NH 4 + and hypertonicity. American Journal of Physiology - Cell Physiology, 2003, 284, C1235-C1246.	4.6	48
72	Association of Apolipoprotein L-1 polymorphisms with blood pressure in three multi-ethnic African studies. Journal of Global Health Reports, 0, 2, .	1.0	0

#	Article	IF	Citations
73	Association of Apolipoprotein L-1 polymorphisms with blood pressure in three multi-ethnic African studies. Journal of Global Health Reports, 0, , .	1.0	0